360.49MMarket Cap-5313P/E (TTM)
3.650High3.460Low117.57KVolume3.500Open3.480Pre Close416.88KTurnover0.26%Turnover RatioLossP/E (Static)98.90MShares5.14052wk High2.21P/B162.50MFloat Cap2.20052wk Low--Dividend TTM44.58MShs Float19.970Historical High--Div YieldTTM5.46%Amplitude1.680Historical Low3.545Avg Price1Lot Size
AC Immune Stock Forum
AC Immune Showcasing its Novel Morphomer-Antibody Drug Conjugate (morADC) Platform for the Treatment of Neurodegenerative Diseases at AAIC 2024
AC Immune SA (NASDAQ: ACIU) will present three oral presentations at the Alzheimer's Association International Conference (AAIC 2024) in Philadelphia, showcasing its precision medicine pipeline for neurodegenerative diseases. The presentations will focus on:
1. [18F]ACI-19626, a first-in-class TDP-43-PET tracer
2. ACI-24.060, an...
In the field of Alzheimer's treatment, Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) and AC Immune SA (NASDAQ: ACIU) have announced an exclusive, worldwide option and license agreement focusing on AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including the promising ...
It's uptrending! Load up now before it's too late! Go Go Go!!!
NEWS
AC Immune Reports First Quarter 2024 Financial Results and Provides a Corporate Update
Positive
Landmark deal with Takeda for ACI-24.060 with $100 million upfront and potential payments of up to $2.1 billion.
ACI-24.060 ABATE Phase 2 trial progressing with results expected in Q2 2024.
ACI-7104.056 VacSYn Phase 2 trial in Parkinson's disease on track.
Three-year cash runway with CHF 104.8 million.
Negative
Reported a net loss of CHF 17.9 million for the quarter.
R&D expe...
No comment yet